Procedural Characteristics and Late Outcomes of Percutaneous Coronary Intervention in the Workup Pre-TAVR.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
23 11 2020
Historique:
received: 04 05 2020
revised: 23 06 2020
accepted: 07 07 2020
pubmed: 19 10 2020
medline: 10 8 2021
entrez: 18 10 2020
Statut: ppublish

Résumé

This study sought to determine, in patients undergoing percutaneous coronary intervention (PCI) during the work-up pre-transcatheter aortic valve replacement (TAVR): 1) the clinical and peri-procedural PCI characteristics; 2) the long-term outcomes; and 3) the clinical events in those patients with complex coronary features. A PCI is performed in about 25% of TAVR candidates, but procedural features and late outcomes of pre-TAVR PCI remain largely unknown. Multicenter study including 1197 consecutive patients who had PCI in the work-up pre-TAVR. A total of 1,705 lesions (1.5 ± 0.7 lesions per patient) were included. Death, stroke, myocardial infarction, and major adverse cardiovascular and cerebrovascular events (MACCE) were recorded, as well as target lesion failure (TLF) and target vessel failure (TVF). One-half of patients exhibited a multivessel disease and the mean SYNTAX (SYNergy between PCI with TAXUS and Cardiac Surgery) score was 12.1 ± 9.1. The lesions were of B2/C type, calcified, bifurcation, and ostial in 49.9%, 45.8%, 21.4%, and 19.3% of cases, respectively. After a median follow-up of 2 (interquartile range: 1 to 3) years, a total of 444 (37.1%) patients presented an MACCE. Forty patients exhibited TVF (3.3%), with TLF identified in 32 (2.7%) patients. By multivariable analysis, previous peripheral artery disease (p < 0.001), chronic obstructive pulmonary disease (p = 0.002), atrial fibrillation (p = 0.003), diabetes mellitus (p = 0.012), and incomplete revascularization (p = 0.014) determined an increased risk of MACCE. In patients with unprotected left main or SYNTAX score >32 (n = 128), TLF, TVF, and MACCE rates were 3.9%, 6.3%, and 35.9%, respectively (p = 0.378; p = 0.065, and p = 0.847, respectively, vs. the rest of the population). Patients undergoing PCI in the work-up pre-TAVR frequently exhibited complex coronary lesions and multivessel disease. PCI was successful in most cases, and TLF and TVF rates at 2-year follow-up were low, also among patients with high-risk coronary features. However, overall MACCE occurred in about one-third of patients, with incomplete revascularization determining an increased risk. These results should inform future studies to better determine the optimal revascularization strategy pre-TAVR.

Sections du résumé

OBJECTIVES
This study sought to determine, in patients undergoing percutaneous coronary intervention (PCI) during the work-up pre-transcatheter aortic valve replacement (TAVR): 1) the clinical and peri-procedural PCI characteristics; 2) the long-term outcomes; and 3) the clinical events in those patients with complex coronary features.
BACKGROUND
A PCI is performed in about 25% of TAVR candidates, but procedural features and late outcomes of pre-TAVR PCI remain largely unknown.
METHODS
Multicenter study including 1197 consecutive patients who had PCI in the work-up pre-TAVR. A total of 1,705 lesions (1.5 ± 0.7 lesions per patient) were included. Death, stroke, myocardial infarction, and major adverse cardiovascular and cerebrovascular events (MACCE) were recorded, as well as target lesion failure (TLF) and target vessel failure (TVF).
RESULTS
One-half of patients exhibited a multivessel disease and the mean SYNTAX (SYNergy between PCI with TAXUS and Cardiac Surgery) score was 12.1 ± 9.1. The lesions were of B2/C type, calcified, bifurcation, and ostial in 49.9%, 45.8%, 21.4%, and 19.3% of cases, respectively. After a median follow-up of 2 (interquartile range: 1 to 3) years, a total of 444 (37.1%) patients presented an MACCE. Forty patients exhibited TVF (3.3%), with TLF identified in 32 (2.7%) patients. By multivariable analysis, previous peripheral artery disease (p < 0.001), chronic obstructive pulmonary disease (p = 0.002), atrial fibrillation (p = 0.003), diabetes mellitus (p = 0.012), and incomplete revascularization (p = 0.014) determined an increased risk of MACCE. In patients with unprotected left main or SYNTAX score >32 (n = 128), TLF, TVF, and MACCE rates were 3.9%, 6.3%, and 35.9%, respectively (p = 0.378; p = 0.065, and p = 0.847, respectively, vs. the rest of the population).
CONCLUSIONS
Patients undergoing PCI in the work-up pre-TAVR frequently exhibited complex coronary lesions and multivessel disease. PCI was successful in most cases, and TLF and TVF rates at 2-year follow-up were low, also among patients with high-risk coronary features. However, overall MACCE occurred in about one-third of patients, with incomplete revascularization determining an increased risk. These results should inform future studies to better determine the optimal revascularization strategy pre-TAVR.

Identifiants

pubmed: 33069647
pii: S1936-8798(20)31500-4
doi: 10.1016/j.jcin.2020.07.009
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2601-2613

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Author Relationship With Industry Dr. Faroux has received fellowship support from Institut Servier and the Association Régionale de Cardiologie de Champagne-Ardenne; and has received research grant support from Biotronik, Edwards Lifesciences, and Medtronic. Dr.Rodés-Cabau has received institutional research grants from Edwards Lifesciences, Medtronic, and Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Laurent Faroux (L)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Francisco Campelo-Parada (F)

Cardiology Department, Hôpital Universitaire de Toulouse, Toulouse, France.

Erika Munoz-Garcia (E)

Cardiology Department, Hospital Universitario Virgen de la Victoria, Malaga, Spain.

Luis Nombela-Franco (L)

Cardiology Department, Instituto Cardiovascular, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.

Quentin Fischer (Q)

Cardiology Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Pierre Donaint (P)

Cardiology Department, Reims University Hospital, Reims, France.

Vicenç Serra (V)

Cardiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Gabriela Veiga (G)

Cardiology Department, Hospital Marques de Valdecilla, Santander, Spain.

Enrique Gutiérrez (E)

Cardiology Department, Hospital Gregorio Marañon, Madrid, Spain.

Victoria Vilalta (V)

Cardiology Department, Hospital Germans Trias i Pujol, Badalona, Spain.

Alberto Alperi (A)

Cardiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.

Ander Regueiro (A)

Cardiology Department, Institut Clínic Cardiovascular, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.

Lluis Asmarats (L)

Cardiology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain.

Henrique B Ribeiro (HB)

Cardiology Department, Heart Institute, University of São Paulo, São Paulo, Brazil.

Anthony Matta (A)

Cardiology Department, Hôpital Universitaire de Toulouse, Toulouse, France.

Antonio Munoz-Garcia (A)

Cardiology Department, Hospital Universitario Virgen de la Victoria, Malaga, Spain.

German Armijo (G)

Cardiology Department, Instituto Cardiovascular, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.

Marina Urena (M)

Cardiology Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Damien Metz (D)

Cardiology Department, Reims University Hospital, Reims, France.

Eduard Rodenas-Alesina (E)

Cardiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Jose Maria de la Torre Hernandez (JM)

Cardiology Department, Hospital Marques de Valdecilla, Santander, Spain.

Eduard Fernandez-Nofrerias (E)

Cardiology Department, Hospital Germans Trias i Pujol, Badalona, Spain.

Isaac Pascual (I)

Cardiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.

Pedro Perez-Fuentes (P)

Cardiology Department, Institut Clínic Cardiovascular, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.

Dabit Arzamendi (D)

Cardiology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain.

Diego Carter Campanha-Borges (DC)

Cardiology Department, Heart Institute, University of São Paulo, São Paulo, Brazil.

David Del Val (D)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Thomas Couture (T)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Josep Rodés-Cabau (J)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. Electronic address: josep.rodes@criucpq.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH